0001745020
false
0001745020
2023-07-13
2023-07-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date Earliest Event Reported):
July 13, 2023
Theseus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40869 |
|
83-0712806 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
314 Main Street
Cambridge, Massachusetts |
|
02142 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(857) 400-9491
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on
which
registered |
Common stock, par value $0.0001 per share |
|
THRX |
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Condition. |
On July 13,
2023, Theseus Pharmaceuticals, Inc. (the “Company”) issued a press release which announced that its cash, cash equivalents,
and marketable securities is expected to be approximately $234 million as of June 30, 2023.
The financial
results included in the press release are unaudited and preliminary estimates that (i) represent the most current information available
to management as of the date of this Current Report on Form 8-K, (ii) are subject to completion of financial closing and procedures
that could result in significant changes to the estimated amounts, and (iii) do not present all information necessary for an understanding
of the Company’s financial condition as of and its results of operations for the six months ended June 30, 2023. Accordingly,
undue reliance should not be placed on such preliminary estimates.
The
information in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as
amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 7.01 | Regulation FD Disclosure. |
On
July 13, 2023, the Company issued a press release titled “Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2
Study and Terminate Development of THE-630 in Patients with GIST.” A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The
information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and
shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of
that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
On
July 13, 2023, the Company announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating
development of THE-630 in patients with gastrointestinal stromal tumors.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Theseus Pharmaceuticals, Inc. |
|
|
|
|
By: |
/s/ Bradford D. Dahms |
|
|
Name: |
Bradford
D. Dahms |
|
|
Title: |
Chief
Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
Date: July 13, 2023
Exhibit 99.1
Theseus Pharmaceuticals to Discontinue Enrollment
in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-- Decision follows two dose-limiting toxicities
related to hand-foot skin reaction observed in Cohort 7 (27 mg) --
-- Company prioritizing THE-349, a potentially
best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 --
--Theseus announces new program targeting KIT
for patients with early-line GIST; development candidate nomination expected in the H1 2024 --
-- Development candidate nomination from BCR-ABL
program also expected in H1 2024 --
-- $234 million in cash, cash equivalents, and
marketable securities as of June 30, 2023; runway extended into 2026 --
Cambridge, Mass., July 13, 2023 /PRNewswire/
-- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving
the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced
that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal
stromal tumors (GIST).
Theseus previously released initial dose escalation
data from the ongoing phase 1/2 trial, which employs a standard 3 + 3 dose escalation design, on May 25, 2023. As of the April 21,
2023 data cutoff date, 23 patients had been dosed through Cohort 6 (18 mg) and 2 patients had been enrolled in Cohort 7 (27 mg). As of
May 25, those 2 patients in Cohort 7 had cleared the dose-limiting toxicity (DLT) observation period without experiencing a DLT.
Following the data release on May 25, the
third patient enrolled in Cohort 7 experienced grade 3 hand-foot skin reaction (HFSR), which required an expansion of the cohort to 6
patients. Subsequently, one of the patients enrolled in the Cohort 7 expansion group experienced grade 2 HFSR, which required a dose interruption
of ≥7 days. Both the grade 3 HFSR and the grade 2 HFSR necessitating ≥7 days dose interruption were determined to be DLTs according
to the study protocol. Therefore, with 2 out of 6 patients experiencing a DLT, the 27 mg dose exceeds the maximum tolerated dose (MTD).
The Company does not believe that THE-630 has a differentiated profile at doses below 27 mg, which would provide exposure well below the
target level of 100 nanomolar average concentration. As a result, the Company has made the decision to terminate the development of THE-630
in GIST. Patients currently enrolled in the trial will continue to receive THE-630 until a treatment discontinuation criterion is met.
As of July 10, 2023, 32 patients have been
treated with THE-630 across 7 dose levels (3 mg to 27 mg). Six patients developed grade 1 to 3 HFSR (3 patients in the 27 mg cohort, 2
patients in the 18 mg cohort, and 1 patient originally in the 9 mg cohort after intra-patient dose escalation to 18 mg). Grade 3 HFSR
was only observed in a patient who started treatment at 27 mg. HFSR was not observed at doses of 12 mg or lower. No significant skin toxicity
was observed in preclinical toxicology studies. The Company is analyzing trial data to inform the feasibility of developing low dose THE-630
for KIT-associated mast cell-driven inflammatory indications, given its potent inhibition of wild-type KIT observed in preclinical assays.
Theseus has continued an extensive medicinal chemistry
effort to target KIT, which has led to the discovery of a series of chemically distinct, highly selective, pan-variant KIT inhibitors
for the treatment of early-line GIST. Theseus plans to nominate a development candidate from this series in the first half of 2024.
“We are disappointed that we will not be
able to achieve the target exposure for pan-variant inhibition with THE-630, as we continue to believe a therapy with potent activity
against all major classes of activating and resistance mutations in KIT has the potential to confer significant clinical benefit, given
the unmet need in GIST,” said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. “On behalf of the entire
Theseus team, I would like to thank the patients, their caregivers, and the investigators and site staff who participated in this
study. We remain committed to helping GIST patients with plans to nominate a new, highly selective pan-variant KIT inhibitor candidate
for GIST in the first half of 2024. Moving forward, we are excited to have THE-349 as our next near-term clinical program, with its potential
best-in-class profile as a fourth generation EGFR inhibitor appropriate for both monotherapy and combination approaches.”
Strategic Priorities:
| · | Advance THE-349 into clinical studies: THE-349 is a potentially best-in-class fourth-generation epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of EGFR mutant non-small cell lung cancer. |
| o | Preclinical data demonstrate THE-349 can potently inhibit all major classes of EGFR activating
and resistance mutations observed in a post-first- or later-line osimertinib setting, possesses kinome and wild-type EGFR selectivity,
and has central nervous system (CNS) activity. |
| o | IND-enabling toxicology studies have been completed, and Theseus remains on track to submit an Investigational
New Drug Application (IND) for THE-349 in the fourth quarter of 2023, and commence its clinical program as soon as possible thereafter,
subject to clearance of the IND by the U.S. Food and Drug Administration. |
| · | Advance BCR-ABL Program: Theseus aims to develop a potent and selective, next-generation, pan-variant
BCR-ABL TKI candidate that optimizes the balance of safety and efficacy for patients with relapsed/refractory chronic myelogenous leukemia
(CML) and patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). |
| o | Theseus plans to pursue clinical development in patients with CML who have been previously treated with
a second-generation TKI or have the T315I mutation, and in newly diagnosed patients with Ph+ ALL. |
| o | Theseus plans to nominate a development candidate for this program in the first half of 2024. |
| · | Advance KIT program for GIST: KIT mutant GIST remains an area of major unmet medical need, requiring a
pan-variant molecule to target all major activating and resistance mutations in KIT, with high selectivity, for use in early-line patients. |
| o | Theseus has continued an extensive medicinal chemistry effort to target KIT which has led to the discovery
of a series of chemically distinct, highly selective, pan-variant KIT inhibitors for the treatment of early-line GIST. |
| o | Theseus plans to nominate a development candidate from this series in the first half of 2024. |
| · | As of June 30, 2023, the Company had approximately $234 million in cash, cash equivalents, and marketable
securities. Theseus expects its current cash, cash equivalents, and marketable securities to fund operations and capital expenditures
into 2026 based on its current operating plan. |
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative
targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target
all classes of cancer-causing and resistance mutations that lead to clinically relevant variants in a particular protein in a given type
of cancer. Theseus is developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated
resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), a pan-variant BCR-ABL inhibitor
for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute
lymphoblastic leukemia (ALL), and a next-generation, highly selective, pan-variant KIT inhibitor for the treatment of early-line GIST.
For more information, visit www.theseusrx.com.
Cautionary Statement Regarding Forward Looking
Statements
Certain statements included in this press release
are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may,"
"will," "estimate," "project," "anticipate," "expect," "plan," "predict,"
"potential," “on track”, "seem," "outlook," "continue," "intend," and similar
expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these
words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements
regarding: the discontinuation of the THE-630 phase 1/2 clinical trial; Theseus’ plans with respect to its BCR-ABL and next generation
KIT programs, including the intention to nominate a development candidate for such programs in the first half of 2024; the timing for
filing an Investigational New Drug Application for THE-349; and the Company’s expectations regarding its cash runway.
Actual results may differ materially from those
indicated by such forward-looking statements as a result of various important risks, uncertainties and other factors, including, but not
limited to: uncertainties inherent in preclinical studies and clinical trials; risks and uncertainties regarding whether results from
preclinical studies and clinical trials will be predictive of the results of future trials; risks related to the expected timing of submissions
to regulatory authorities and timing for review by such regulatory authorities; risks related to market volatility and global economic
conditions; and other risks, uncertainties and other factors such as those described from time to time in the reports Theseus files with
the Securities and Exchange Commission (SEC), including Theseus' Form 10-K for the year ended December 31, 2022 and subsequent
Quarterly Reports on Form 10-Q which will be on file with the SEC and available on the SEC's website at https://www.sec.gov/. However,
new risk factors and uncertainties may emerge from time to time which may cause actual results to differ materially from those anticipated
or implied by the forward-looking statements in this press release, and it is not possible to predict all risk factors and uncertainties.
Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained
in this press release are based on the current expectations of Theseus' management team and speak only as of the date hereof, and Theseus
specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or
otherwise, except as required by law.
Investor and Media Contact
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Theseus Pharmaceuticals (NASDAQ:THRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Theseus Pharmaceuticals (NASDAQ:THRX)
Storico
Da Mag 2023 a Mag 2024